<DOC>
	<DOC>NCT00387205</DOC>
	<brief_summary>This study is a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.</brief_summary>
	<brief_title>Study To Assess Long Term Safety Of Pazopanib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy). Able to understand and provide written informed consent Women and men agree to use protocol specific birth control measures The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer If you are pregnant or breast feeding Your doctor does not think you would be a good candidate for the study Poorly controlled high blood pressure Subject is unwilling or unable to follow the procedures outlined in the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>chronic administration</keyword>
	<keyword>monotherapy and combination therapies</keyword>
	<keyword>solid</keyword>
	<keyword>lapatinib (TYKERB, TYVERB)</keyword>
	<keyword>malignant tumor</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GW786034</keyword>
	<keyword>cancer</keyword>
	<keyword>safety</keyword>
</DOC>